SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

ICP is trending due to renewed community excitement around its technology as a decentralized internet solution and potential to challenge centralized cloud services. Discussions highlight its unique architecture, interoperability with other blockchains, and recent developments like Caffeine AI, driving speculation about future growth and adoption. Some traders are drawing comparisons to ZCash's previous price movements, while others caution against shorting and emphasize long-term potential.

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin is trending as community members discuss its potential within the decentralized storage and AI infrastructure space, drawing comparisons to competitors like Storj and Amazon AWS. Bullish sentiment is fueled by speculation around altcoin season and the possibility of Filecoin reaching new highs, with some highlighting its real-world utility and partnerships. Some users are also discussing possible dilution of coins affecting price action.

Aventus Network

Aventus Network ($AVT) is trending as community members highlight its strong technology, recent company updates (especially around Aventus Cloud), partnerships with Vodafone, Heathrow airport, and Polkadot, and potential for a breakout. Traders are watching for increased volume, believing that $AVT is undervalued with significant upside potential due to its small circulating supply and Polkadot integration. Some compare it to other low cap coins like $MUSE, anticipating a potential pump.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending as community members discuss its potential, partnerships with projects like Aventus, and the impact of the new 2.1 billion token hard cap.  Some investors express frustration with DOT's price action and question its long-term viability, while others remain optimistic due to staking rewards and potential web3 integrations. Broader market catalysts like potential ETF approvals and shifts in Federal Reserve policy are also being closely watched for their potential influence on DOT's price.

Sei is a high-performance Layer 1 blockchain that scales the EVM with parallelized execution, enabling faster transactions, low fees, and seamless smart contract deployment. Sei removes traditional blockchain bottlenecks while maintaining full Ethereum compatibility. The upcoming Giga upgrade will deliver 50x improvements in EVM throughput, optimizing execution, consensus, and storage to push blockchain performance to web2 levels.

SEI is trending as community members discuss its potential compared to other Layer-1 blockchains and debate whether it's a worthwhile investment. Recent news, including listings on Robinhood and developments around Real World Assets (RWAs), are sparking interest. Some traders are comparing it to Solana, noting its speed and potential for growth, while others express concerns about its price action and developer activity.

The KARRAT protocol is a decentralized gaming infrastructure layer, supported by $KARRAT and empowered by a truly decentralized community with a shared vision embracing gaming, entertainment and AI products catering for the new era.  To accelerate the evolution of gaming, entertainment, and AI-driven experiences with blockchain technology and a truly empowered community.  The KARRAT protocol pioneers a decentralized framework in gaming and entertainment, combining blockchain with community-driven collaboration. $KARRAT can animate ecosystems of games and products and the protocol makes tools available to support these industries and the adoption of KARRAT technology provides a unique, personalized gaming experience.

KARRAT

Karrat is trending as the community discusses its potential in web3 gaming, especially with its integration into My Pet Hooligan and upcoming use cases. Some traders are noting recent price movements and suggesting strategic entry points, while others debate the impact of upcoming token unlocks. Overall, the conversation reflects anticipation for Karrat's role in the evolving blockchain gaming landscape and AI-integrated entertainment.

Sun Communities, Inc. provides real estate management services. The firm operates through the following segments: Manufactured Home Communities, Recreational Vehicle, and Marina. The Manufactured Home Communities segment owns, operates, and develops manufactured housing communities and is in the business of acquiring, operating, and developing ground up communities to provide housing solutions. The Recreational Vehicle segment focuses on the development of recreational vehicle resorts and is in the business of acquiring, operating and developing ground up resorts throughout the U.S. and in Ontario, Canada. The Marina segment operates marinas and is in the business of acquiring and operating marinas throughout the U.S. The company was founded in 1975 and is headquartered in Southfield, MI.

Sun Communities, Inc.

Sun Communities ($SUI) is trending due to a mix of factors, including RBC Capital and Evercore ISI Group upgrading the stock to Outperform, sparking community discussion about its potential. The DTCC listing @21shares $SUI spot ETF (TSUI) may also be contributing to the increased interest. Conversations also involve comparing SUI to other cryptocurrencies like SOL and XRP, with some seeing it as a key player in the evolving crypto landscape, particularly within DeFi and AI-driven commerce.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending as investors discuss its potential resurgence, fueled by strong Q3 performance and a pivot towards high-margin sectors like pharmaceuticals and advanced materials. Community talking points revolve around the company's debt reduction, undervalued real estate assets, and potential government support for domestic manufacturing. Some users are sharing positive due diligence, while others are speculating on potential announcements and catalysts that could drive the stock higher, including possible meme stock status.

P8BCI Is the CCM Creator Capital Markets Creator token created by Nick Wray, intended to form a community for talking about his journey with ALS, his experiences with Telepathy BCI experiments, as well as his experiences and journey through the Solana blockchain, and cryptocurrency world of Web 3. In addition to this, prior to his progression of ALS Nick was an avid drummer, a creative, and an enjoyer of philosophical discussion - and enabled now by his BCI explores creating, and in addition to sharing his story, interacting with the community forming around his experiences.

Telepath8

Telepath8 ($P8BCI) is trending amid community excitement over its developer's purported connection to Neuralink and Elon Musk. Discussions center on the project's innovative development process and potential synergies with neurotechnology, fueling bullish sentiment.

Lowe's Companies, Inc. engages in the retail sale of home improvement products. The firm offers products for maintenance, repair, remodeling, home decorating, and property maintenance. It also provides home improvement products in the following categories: appliances, seasonal & outdoor living, lumber, lawn & garden, kitchens & bath, hardware, building materials, millwork, paint, rough plumbing, tools, electrical, flooring, and décor. The company was founded in 1946 and is headquartered in Mooresville, NC.

Lowe`s Cos., Inc.

Lowe's Companies, Inc.

Lowe's is trending as community members discuss analyst upgrades and the company's Q3 earnings report, which beat expectations despite a challenging DIY market. The community is weighing the impact of a strong Pro segment and potential benefits from future interest rate cuts, while also noting that the stock dipped despite the positive news. Some see a buying opportunity, while others are taking profits and considering options strategies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Eli Lilly CEO Dave Ricks' comments come after the company reported third-quarter earnings results that topped estimates and hiked its full-year guidance.</li><li>Ricks stated “triple-acting” Retatrutide promises to have an even bigger impact on weight loss than Zepbound and Mounjaro.</li><li>In addition to its injectable therapies, the launch of Orforglipron, a daily oral pill for weight loss, is also in the pipeline.</li></ul>Eli Lilly (LLY) is reportedly looking to expand into pain relief by leveraging the momentum of its weight loss treatments, Mounjaro and Zepbound, which have captured significant share in the fast-growing obesity market.CEO Dave Ricks&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/video/2025/10/30/watch-cnbcs-full-interview-with-eli-lilly-ceo-dave-ricks.html">told</a> CNBC on Thursday that the company sees potential to move beyond traditional weight management into therapies that address pain associated with obesity. According to the company’s third-quarter earnings report, trials are underway targeting knee and back pain, with a focus on patients who are overweight or have obesity.<blockquote>“We hope to prove that patients who are overweight or have obesity with chronic knee pain find relief with Retatrutide in addition to losing weight.”&nbsp;– Dave Ricks, CEO, Eli Lilly</blockquote>Ricks stated “triple acting” Retatrutide promises to have an even bigger impact on weight loss than Zepbound and Mounjaro.&nbsp; “The first study that we’ll read out for that triple-acting agent will actually be in knee pain,” he said, adding that weight loss drugs have both direct and indirect anti-inflammatory effects.<h2 class="st-heading-2">Eli Lilly Hikes Full-Year Guidance</h2>Ricks’ comments follow the company's upbeat third-quarter (Q3) results and increased full-year guidance, issued earlier on Thursday. The pharmaceutical giant now expects its fiscal 2025 revenue to be between $63 billion and $63.5 billion, up from its previous guidance of $60 billion to $62 billion.<a href="http://stocktwits.com/symbol/LLY">LLY’s stock</a> gained 3.7% in morning trade, with retail sentiment around the pharma giant on Stocktwits improving to ‘bullish’ from ‘bearish’ territory over the past day. Retail chatter increased to ‘high’ from ‘low’ levels.Lilly reported a strong international uptake for its products, rolling out Mounjaro earlier this year in markets including India, China, and Brazil. “We’re seeing global demand for this product,” the CEO said, adding that both Mounjaro and Zepbound have performed well in their early years, signaling the potential for sustained growth in the future.<h2 class="st-heading-2">Oral Pill Expansion</h2>In addition to its injectable therapies, Lilly is preparing to launch Orforglipron, a daily oral pill, which Ricks said has completed Phase 3 trials, with submission expected in Q4. The CEO highlighted that oral therapy meets patient demand for a less intrusive option than weekly injections.&nbsp;He said it also addresses practical barriers in middle-income countries where refrigeration and cold-chain requirements limit access to injectable products. “We think that’s a great spot for Orforglipron,” the CEO noted, adding that the company expects strong global performance for Orforglipron.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-dips-triggers-800-million-in-crypto-liquidations-after-powells-warning/cLGFrJnR3Dy">Bitcoin Dips, Triggers $800 Million In Crypto Liquidations After Powell’s December Warning</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CEO of Eli Lilly and Company David Ricks speaks at the Economic Club of New York on March 12, 2024 in New York City. (Photo by Spencer Platt/Getty Images)

Eli Lilly CEO Dave Ricks Reportedly Says Company Eyeing Pain Relief Market With Weight Loss Drug Retatrutide 

CEO Dave Ricks told CNBC that the first study the company plans to read out for Retatrutide will be on knee pain.

Eli Lilly CEO Dave Ricks Reportedly Says Company Eyeing Pain Relief Market With Weight Loss Drug Retatrutide

Equity

UnitedHealth Lifts EPS Outlook Despite Mixed Q3 Results: ETFs in Focus

UNH posts mixed Q3 results with a revenue miss but lifts its 2025 EPS outlook, boosting interest in healthcare ETFs like IHF and XLV. 

<ul class="summary-bullets"><li>Short seller Hunterbrook flagged three new deaths linked to the Dexcom G7 reported in&nbsp;the FDA MAUDE database.</li><li>It stated that at least 13 G7 users have died since the device launched in 2023.&nbsp;</li><li>This is&nbsp;the second time the firm has published data around Dexcom, after first disclosing its short position in September.</li></ul>Dexcom (DXCM) shares slipped in midday trade on Tuesday after short seller Hunterbrook reported three additional deaths linked to the company’s G7 continuous glucose monitor.<a href="http://stocktwits.com/symbol/DXCM">DXCM’s stock</a> fell nearly 2%, with retail sentiment on Stocktwits around the company trending in ‘bearish’ territory over the past day.&nbsp; Hunterbrook first&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dexcom-stock-slumps-after-hunterbrook-media-investigation-raises-concerns-about-its-g7-device/chD3f5NR3Tm">disclosed</a> its short position in September, citing inaccurate G7 readings that allegedly sent patients to ICUs or&nbsp;led to worse outcomes.&nbsp;<h2 class="st-heading-2">FDA Data Shows Device Risks</h2>The short seller&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://hntrbrk.com/dexcom2/">said</a> the new deaths were documented in the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database, which tracks adverse events involving medical devices. It noted that while the reports do not necessarily prove the device caused the deaths, they help regulators and manufacturers flag potential risks.Hunterbook highlighted that one report described a 69-year-old man whose G7 sensor failed to provide readings, and a second involved a patient using the G7 with an automated insulin pump, whose inaccurate reading may have contributed to fatal ketoacidosis. The third report cited a woman who relied on the G7’s receiver alarms, which had been recalled days earlier for failing to sound properly.<h2 class="st-heading-2">Ongoing Scrutiny And Product Concerns</h2>The short seller stated that at least 13 G7 users have died since the device launched in 2023.&nbsp;It said that even the FDA issued a warning letter to Dexcom in March 2025 following a surprise inspection that revealed unauthorized design changes to a key component, which internal testing found inferior.&nbsp;Dexcom reportedly continued selling the device despite these findings. The short seller stated that the resulting controversy has triggered executive departures, insider selling, and patients returning to older G6 devices or switching to competitors, while ongoing lawsuits and regulatory scrutiny weigh on the company.DXCM’s stock has declined 11% this year and more than 8% since Hunterbrook first disclosed its short position.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-holds-near-114-k-ahead-of-fed-rate-decision-sol-xrp-edge-higher/cLGjgObR3H9">Bitcoin Holds Near $114K Ahead of Fed Rate Decision — SOL, XRP Edge Higher</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

Dexcom Shares Slide After Short Seller Flags 3 Additional Deaths From G7 Devices

Short seller Hunterbrook stated that at least 13 G7 users have died since the device launched in 2023. 

<ul class="summary-bullets"><li>While the consensus EPS estimate suggests a decline from a year ago, revenue is expected to rise by more than 12% year over year.</li><li>A retail user expected a “well-thought-out earnings call with a road to a bright future, no matter what the numbers say.”</li><li>Stung by the headwinds, UnitedHealth stock is down more than 23% this year.</li></ul>Healthcare services giant UnitedHealth, Inc. (UNH), which has been facing company-specific, macro, and geopolitical challenges, is scheduled to announce its quarterly results before the market opens on Tuesday.Stung by the headwinds,&nbsp;<a href="https://stocktwits.com/symbol/UNH">UnitedHealth stock</a> is down more than 23% this year.<h2 class="st-heading-2">What Street Expects For UNH’s Q3</h2>According to the Fiscal.ai-compiled consensus estimates, UnitedHealth is expected to report adjusted earnings per share (EPS) of $2.81 and revenue of $113.06 billion. While the consensus EPS estimate suggests a decline from the year-ago’s $3.57, revenue is expected to rise over 12% year-over-year (YoY).In a mid-September note, Morgan Stanley analyst Erin Wright said he came away from an investor dinner with the UNH management team incrementally positive. He noted that the management team, led by CEO Stephen Hemsley, oozed conviction in a turnaround, driven by Medicare Advantage (MA) and Optum Health improvement.Among the headwinds the company faces are higher medical loss ratios that have pressured margins, pricing,&nbsp;as well as operational mistakes in its MA and Affordable Care Act (ACA) businesses.&nbsp;It also faces criminal investigations into the MA billing practices, and the business practices of its&nbsp;Optimum unit, as well as other lawsuits for allegedly improperly denying claims.The company withdrew its full-year 2025 guidance in mid-May, replaced Andrew Witty as CEO with former CEO Hemsley, citing unexpected medical costs and challenges with its Medicare strategy. It, however, reinstated the annual guidance when it released its second-quarter results in late July. The current outlook calls for revenue of $445.5 billion to $448 billion and adjusted EPS of at least $16.<h2 class="st-heading-2">How Retail Is Positioned For Q3 Results</h2>Retail sentiment toward UnitedHealth stock flipped to ‘bullish’ by early Tuesday from ‘bearish’ a day ago. The message volume on the stream has picked up pace to ‘high’ levels.<figure class="image"><img style="aspect-ratio:623/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_28_at_1_35_06_AM_png_d1fda1994a.webp" alt="Screenshot 2025-10-28 at 1.35.06 AM.png" width="623" height="53"><figcaption>UNH sentiment and message volume as of 1:30 a.m ET, Oct. 28 | source: Stocktwits</figcaption></figure>A bullish user looked ahead to better performance after a “kitchen-sink” second quarter.<stembedurl>https://stocktwits.com/newtwo99/message/633929931</stembedurl>Another user expected a “well-thought-out earnings call with a road to a bright future no matter what the numbers say.” If the numbers come in better than expected, they see it as an added advantage.<stembedurl>https://stocktwits.com/PhoenixRisingMD/message/633928829</stembedurl><h2 class="st-heading-2">Wall Street Lift Price Targets Ahead Of Q3 Print</h2>Since the start of October, UnitedHealth’s stock has received a string of price target hikes, with the updated price targets ranging from $335 to $433, according to the Fly. While lifting its price target to $409 from $317 earlier this month, Jefferies analyst David Windley said he sees upside for MA margins in 2026, thanks to assertive group repricing efforts. The analyst has a ‘Buy’ rating on the stock.Goldman Sachs initiated coverage of the UnitedHealth stock with a ‘Buy rating’ and $406 price target. While the firm believes that the managed care industry faces its most significant underwriting downturn in over 15 years, it recommended increased exposure to MA, factoring in a margin recovery phase beginning in 2026.&nbsp;After bumping up the price target to $430 from $300, Mizuho, which has an ‘Overweight’ rating, noted increased earnings visibility on key issues and rotation into the healthcare sector.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-nxp-semiconductor-stock-rose-in-today-s-after-hours/cLGjTBXR3ur">Why NXP Semiconductor Stock Rose In Today’s After-hours</a>

In this photo illustration, a smartphone displays the logo of UnitedHealth Group Incorporated. (Photo illustration by Cheng Xin/Getty Images)

UnitedHealth Stock In Spotlight Ahead Of Earnings: Retail Traders Bet On Recovery After ‘Kitchen-Sink’ Q2

While the consensus EPS estimate suggests a decline from a year ago, revenue is expected to rise by more than 12% year over year.

UnitedHealth (UNH) Stock In Spotlight Ahead Of Earnings: Retail Traders Bet On Recovery After ‘Kitchen-Sink’ Q2

4 Sector ETFs & Stocks to Gain Despite Lower-Than -Expected Inflation

September records lower-than-expected inflation! Energy (OIH), Restaurants (EATZ), Healthcare (XLV) and Transportation (XTN) ETFs may still shine in the near term.

Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs

Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs. 

<ul class="summary-bullets"><li>The Trump administration is preparing a Section 301 investigation to assess whether U.S. trading partners underpay for prescription drugs, a move that could pave the way for new tariffs.</li><li>Earlier this month, the White House confirmed generic drugs would be excluded from potential duties, reversing earlier discussions under the Section 232 national security review.</li><li>The probe expands Trump’s broader effort to pressure pharmaceutical companies and foreign governments to “equalize” drug prices globally.</li></ul>President Donald Trump’s administration reportedly is stepping up pressure on U.S. trading partners over drug costs, preparing a Section 301 investigation under the Trade Act of 1974 to determine whether countries are underpaying for prescription medicines.The move could pave the way for new tariffs and marks a renewed escalation in Trump’s campaign to “equalize” drug prices globally, according to a Financial Times&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/bce66d6e-57f7-40a2-8225-06a8f50ff657">report</a>, citing three people familiar with the matter.Trump has long argued Americans pay disproportionately high prices for the same drugs sold abroad, citing last week that “in London, you’d buy a certain drug for $130 … and in New York, you pay $1,300 for the same thing.”&nbsp;U.S. drug prices average nearly three times higher than in other developed economies, according to the Rand Corporation. Novo Nordisk’s Ozempic, for instance, costs about $936 per month in the U.S., versus $147 in Canada and $83 in France, KFF data show.<h2 class="st-heading-2">Generic Drugs Excluded From Tariff Plans</h2>Earlier this month, the White House<a href="https://stocktwits.com/news-articles/markets/equity/trump-walks-back-generic-drug-tariffs-after-white-house-clash-over-prices-supply-risks/ch67JdhR30E"> said it isn’t planning tariffs on generic drugs</a>, narrowing the scope of its trade actions. Officials had been weighing such duties under Section 232 of the Trade Expansion Act, which permits tariffs on national security grounds.White House spokesman Kush Desai said the administration “is not actively discussing imposing Section 232 tariffs against generic pharmaceuticals.” The Commerce Department also said such tariffs were unlikely, marking a reversal from Trump’s 2023 campaign pledge to restore domestic production of all essential medicines.Advisers, including members of the Domestic Policy Council and health aide Theo Merkel, warned tariffs on generics could raise prices and cause shortages, given that India supplies nearly half of U.S. generic drugs. Commerce officials, however, continue to explore quotas or incentives to rebuild U.S. drug manufacturing capacity.<h2 class="st-heading-2">Broader Pharma Trade Push&nbsp;</h2>The Section 301 move expands Trump’s broader effort to tie drug pricing policy to trade leverage. Earlier this year, he demanded that pharmaceutical companies offer the U.S. their best global price or face penalties.Major firms, including Pfizer, AstraZeneca, Novo Nordisk, and Eli Lilly, have all held pricing talks with the White House. Trump previously reached a deal with the EU to cap drug import tariffs at 15% and is negotiating with the U.K. for lower duties in exchange for higher payments to drugmakers.While Trump last month threatened 100% tariffs on branded drugs to force companies to expand U.S. manufacturing, those measures have yet to materialize. Officials said firms will be given time to invest domestically and demonstrate pricing reforms.Desai said the White House is pursuing a “multi-faceted approach” that could include federal grants or loans, potentially with funding from foreign partners like Japan, to strengthen U.S. drug supply chains and reduce dependence on imports.<h2 class="st-heading-2">Stocktwits Traders See Muted Interest For Healthcare ETFs</h2>On Stocktwits, retail sentiment toward the Health Care Select Sector SPDR Fund (XLV) was ‘bearish’ and toward the iShares Global Healthcare ETF (IXJ) was ‘neutral,’ both amid ‘low’ message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> is up 7%, while&nbsp;<a href="https://stocktwits.com/symbol/IXJ">IXJ</a> has gained 9%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

Trump Steps Up Pressure On Trading Partners Over Drug Costs, Plans Section 301 Review: Report

The probe expands Trump’s broader effort to pressure pharmaceutical companies and foreign governments to “equalize” drug prices globally.

ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook

 JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.


Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

Zacks Investment Ideas feature highlights: XLP, KXI, XLU, VPU, VHT and XLV

As AI-fueled markets show bubble risks, defensive ETFs like XLP, XLU, and XLV offer investors stability and downside protection.

SSgA Active Trust - Health Care Select Sector SPDR

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

XLV
Health Care Select Sector SPDR Fund

Feed

News

Sentiment

Fundamentals

Info

Latest XLV News

XLVHealth Care Select Sector SPDR Fund